FTC’s New Commissioner, Alvaro Bedoya, May Bolster Tougher Stance On Pharma Oversight
Democrats gain majority on Federal Trade Commission with Bedoya’s swearing in. His positions on technology and digital privacy suggest he will align with commissioners who have advocated stricter review of pharma mergers.
You may also be interested in...
FTC May Go After Pharma Bundling, Rebates, Patent Processes With Reactivation of Section 5
Agency restores long dormant enforcement of section of FTC Act prohibiting businesses from using ‘unfair methods of competition,’ expanding types of corporate behavior subject to enforcement action.
US FTC Targets Fake Online Reviews, Expanded Liability, With Proposed Endorsement Guides Update
Proposed changes to the FTC’s “Guides Concerning the Use of Endorsements and Testimonials in Advertising” depict an agency looking to crack down on fake reviews and suppression of negative ones, tighten its definition of “clear and conspicuous” disclosures, and clarify that advertisers, endorsers, intermediaries and platforms all can be held liable for their endorsement roles.
FTC And PBMs: Support For Investigation Building But Outcome May Ultimately Disappoint Critics
Federal Trade Commission’s ‘pro-competitive’ perspective could support conclusion that pharmacy benefit managers serve useful role in lowering drug costs, health policy expert suggests. FTC will get an earful about PBM practices, but ‘those complaints could be an indication that competition is working.’